DK2861582T3 - A process for preparing hydroxylated compounds cyclopentylpyrimidin - Google Patents

A process for preparing hydroxylated compounds cyclopentylpyrimidin Download PDF

Info

Publication number
DK2861582T3
DK2861582T3 DK13725042.9T DK13725042T DK2861582T3 DK 2861582 T3 DK2861582 T3 DK 2861582T3 DK 13725042 T DK13725042 T DK 13725042T DK 2861582 T3 DK2861582 T3 DK 2861582T3
Authority
DK
Denmark
Prior art keywords
substituted
unsubstituted
compound
alkyl
salt
Prior art date
Application number
DK13725042.9T
Other languages
Danish (da)
English (en)
Inventor
David Askin
Chong Han
Jonathan W Lane
Travis Remarchuk
Sagar Shakya
C Gregory Sowell
Keith L Spencer
Peter J Stengel
Original Assignee
Array Biopharma Inc
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc, Genentech Inc filed Critical Array Biopharma Inc
Application granted granted Critical
Publication of DK2861582T3 publication Critical patent/DK2861582T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK13725042.9T 2012-05-17 2013-05-17 A process for preparing hydroxylated compounds cyclopentylpyrimidin DK2861582T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US201361785122P 2013-03-14 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (1)

Publication Number Publication Date
DK2861582T3 true DK2861582T3 (en) 2016-08-22

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13725042.9T DK2861582T3 (en) 2012-05-17 2013-05-17 A process for preparing hydroxylated compounds cyclopentylpyrimidin

Country Status (20)

Country Link
US (4) US9416110B2 (enExample)
EP (1) EP2861582B1 (enExample)
JP (1) JP6284928B2 (enExample)
KR (1) KR102067850B1 (enExample)
CN (1) CN104470913B (enExample)
AU (1) AU2013262505B2 (enExample)
BR (1) BR112014028589B1 (enExample)
CA (1) CA2873654C (enExample)
DK (1) DK2861582T3 (enExample)
ES (1) ES2582557T3 (enExample)
IL (1) IL235715A (enExample)
MX (1) MX353384B (enExample)
MY (1) MY169028A (enExample)
NZ (1) NZ702935A (enExample)
PL (1) PL2861582T3 (enExample)
RU (1) RU2643811C2 (enExample)
SG (1) SG11201407616TA (enExample)
SI (1) SI2861582T1 (enExample)
WO (1) WO2013173768A1 (enExample)
ZA (1) ZA201409261B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
CN112898210B (zh) 2013-11-15 2025-02-21 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
PL3197875T3 (pl) * 2014-09-26 2020-03-31 F. Hoffmann-La Roche Ag Sposoby wytwarzania związków (cyklopentylo[d]pirymidyn-4-ylo)piperazynowych
CN109789141B (zh) 2016-08-10 2022-08-26 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
CN120887837A (zh) 2020-06-16 2025-11-04 豪夫迈·罗氏有限公司 用于制备羟基化环戊基嘧啶化合物的方法
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015684A1 (en) 1993-12-12 1995-06-15 Agrogene, Ltd. A novel method to protect plants from fungal infection
WO1998044797A1 (en) 1997-04-07 1998-10-15 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1281604C (zh) * 1999-06-03 2006-10-25 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
CA2526506A1 (en) 2003-06-09 2004-12-16 Boehringer Ingelheim International Gmbh Inhibitors of papilloma virus
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
WO2010120935A1 (en) 2009-04-15 2010-10-21 Abbott Laboratories Anti-viral compounds
BR112012011328A2 (pt) * 2009-10-23 2016-11-22 Lilly Co Eli inibidores de akt
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
ES2588878T3 (es) 2012-05-17 2016-11-07 Array Biopharma, Inc. Proceso para preparar compuestos de ciclopentilpirimidina hidroxilada
ES2582557T3 (es) 2012-05-17 2016-09-13 Array Biopharma, Inc. Proceso para la preparación de compuestos hidroxilados de ciclopentilpirimidina
EP2850200A1 (en) 2012-05-17 2015-03-25 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
LT2858989T (lt) 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
BR112014028585B1 (pt) 2012-05-17 2020-12-22 Genentech , Inc processo para fabricação de aminoácidos, e seus intermediários
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
US20150376198A1 (en) 2013-02-18 2015-12-31 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
EP2968318A4 (en) 2013-03-15 2016-12-14 Shifa Biomedical Corp ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES

Also Published As

Publication number Publication date
EP2861582A1 (en) 2015-04-22
JP6284928B2 (ja) 2018-02-28
CN104470913A (zh) 2015-03-25
JP2015517532A (ja) 2015-06-22
ES2582557T3 (es) 2016-09-13
US20160318877A1 (en) 2016-11-03
HK1208451A1 (en) 2016-03-04
US20180258054A1 (en) 2018-09-13
IL235715A (en) 2017-02-28
KR102067850B1 (ko) 2020-01-17
CA2873654A1 (en) 2013-11-21
NZ702935A (en) 2017-02-24
MY169028A (en) 2019-02-04
RU2643811C2 (ru) 2018-02-06
US20170247337A1 (en) 2017-08-31
US9790190B2 (en) 2017-10-17
MX2014013862A (es) 2015-05-07
MX353384B (es) 2018-01-10
ZA201409261B (en) 2017-05-31
EP2861582B1 (en) 2016-05-25
PL2861582T3 (pl) 2016-11-30
BR112014028589B1 (pt) 2022-08-23
CA2873654C (en) 2021-06-22
US9416110B2 (en) 2016-08-16
US9676730B2 (en) 2017-06-13
RU2014151050A (ru) 2016-07-10
CN104470913B (zh) 2018-07-20
AU2013262505A1 (en) 2015-01-22
IL235715A0 (en) 2015-02-01
KR20150020214A (ko) 2015-02-25
US20150152067A1 (en) 2015-06-04
WO2013173768A1 (en) 2013-11-21
BR112014028589A2 (pt) 2017-07-25
AU2013262505B2 (en) 2017-09-21
SI2861582T1 (sl) 2016-09-30
SG11201407616TA (en) 2015-03-30

Similar Documents

Publication Publication Date Title
AU2013262505B2 (en) Process for making hydroxylated cyclopentylpyrimidine compounds
JP2024524851A (ja) Erk阻害剤を調製するプロセス
AU2019253849B2 (en) Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
EP2850054B1 (en) Process for making amino acid compounds
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208451B (en) Process for making hydroxylated cyclopentylpyrimidine compounds